WELCOME TO SIAMAB THERAPEUTICS, INC.
Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates/glycans. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and overcome chemo-resistance.
Siamab has developed a technology platform that enables the discovery of large numbers of highly specific, high affinity anti-TACA therapeutic antibodies. Siamab has brought together a world-leading team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support our anti-TACA antibody discovery and development programs.
ANGEL-FUNDED SIAMAB COMPLETES $202 MILLION EXIT WITH LARGE COMMERCIAL-STAGE BIOPHARMA - TRANSACTION VALIDATES ANTI-TACA THERAPEUTIC APPROACH FOR TREATMENT OF SOLID TUMORS
August 19, 2019
SIAMAB THERAPEUTICS ANNOUNCES PUBLICATION IN PLOS ONE OF POSITIVE DATA FROM PRECLINICAL STUDIES OF ITS ST1 ANTIBODY THERAPEUTIC IN DEVELOPMENT FOR OVARIAN CANCER
July 27, 2018
SIAMAB THERAPEUTICS ANNOUNCES PUBLICATION OF NEW DATA ON ITS ST1 LEAD PROGRAM IN THE JOURNAL ONCOTARGET
May 1, 2018
SIAMAB THERAPEUTICS TO PRESENT NEW DATA ON ITS ST1 ANTIBODY THERAPEUTIC PROGRAM TARGETING TUMOR-ASSOCIATED STN AND STN+ MYELOID DERIVED SUPPRESSOR CELLS AT THE AACR ANNUAL MEETING 2018
April 4, 2018
SIAMAB THERAPEUTICS TO PRESENT NEW DATA ON ITS ST1 ANTIBODY THERAPEUTIC PROGRAM TARGETING TUMOR-ASSOCIATED STN AND MDSCS AT BIOTECH SHOWCASE™ 2018
January 3, 2018
SIAMAB FEATURED IN OVARIAN CANCER NEWS TODAY: SIAMAB'S ANTIBODY-DRUG CONJUGATES FOR OVARIAN CANCER SEEN TO SUCCEED IN ANIMAL MODELS
November 6, 2017